Azithromycin before anti-TNF treatment for Crohn’s disease
Treatments studied
Part of Digestive system clinical trials.
This Phase 2 trial tests whether taking azithromycin (an antibiotic) before starting infliximab or adalimumab can reduce the chance your body rejects the anti‑TNF medicine. It may help some people get better and keep responding to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18–80 and can sign consent and attend all study visits.
- You have Crohn’s disease (symptoms for at least 3 months) and are starting infliximab or adalimumab.
- You cannot be enrolled in another experimental (interventional) study at the same time.
- You must not be on long-term antibiotics, and you should not have taken antibiotics in the last 4 weeks.
- You should be able to take the study antibiotic as planned (no azithromycin allergy, and not pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medicine options (azathioprine vs methotrexate) when added to adalimumab to treat active Crohn’s disease. It may help determine which add-on works better for people whose Crohn’s is still active despite standard treatments or who can’t take them.
This study tests whether giving a steroid (dexamethasone) before an infliximab infusion can prevent allergic reactions in people with moderate-to-severe Crohn's disease or ulcerative colitis. If you qualify, you will receive either the steroid or a placebo before your infliximab treatment.
This trial tests whether a person's genetic makeup affects how well infliximab works for treating Crohn's disease. It may help doctors predict which patients benefit most from this medication.
This study tests whether combining infliximab (a biologic medicine that reduces inflammation) with azathioprine (an immune-suppressing drug) is safe and effective for children with moderate to severe Crohn's disease who haven't tried these medicines before.
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
This study tests whether adding a specific gut bacteria (Akkermansia muciniphila) to the standard Crohn's treatment infliximab helps heal the intestinal lining better. This could improve long-term control of Crohn's disease.
Hear when a new Crohn's Disease Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.